adjective Referring to an effect that suppresses or inhibits oestrogenic activity.
noun An agent that counters oestrogenic activity.


adjective Referring to an effect that suppresses or inhibits estrogenic activity noun A general term for an agent that counters estrogenic activity


Counteracting or suppressing estrogenic activity.
Synonym(s): antioestrogenic.
References in periodicals archive ?
It can be attributed to the antiestrogenic activity of BPA as estrogen is known to increase the excitability of myometrium.
Their name says it all, as phytoestrogens exhibit mild estrogenic and antiestrogenic activity in the body.
Lack of estrogenic or antiestrogenic actions of soy isoflavones in an avian model: The Japanese quail.
Arnold, The Estrogenic and Antiestrogenic Activities of Phytochemicals with the Human Estrogen Receptors Expressed in Yeast.
3 The antiestrogenic action of gestrinone, associated with its ability to reduce estradiol production by the ovary, may further inhibit endometrial proliferation in endometriosis and allow effective treatment of endometriosis-related pain.
The estrogenic and antiestrogenic activities of phytochemicals with the human receptor expressed in yeast steroids, 62: 365-372.
Hansen, Estrogenic and antiestrogenic actions of PCBs in the female rat: In vitro and in vivo studies", Reprod.
When tested in normal human mammary tissue explant cultures, ospemifene was also found to have antiestrogenic, growth inhibitory effects, similar to raloxifene and tamoxifen.
Letrozole as an aromatase inhibitor induces ovulation in women with PCOS without having antiestrogenic effects on the endometrium (10).
Resveratrol has the capability to act in an estrogenic or antiestrogenic manner to inhibit or promote breast cancer progression, dependent on concentration, and can bind to and regulate gene transcription through estrogen receptor [alpha] and [beta] isoforms (6-8).
The phloretin glucoside phloridzin plays a role of phytoestrogen with estrogenic and antiestrogenic activity (Wang et al.
The randomized, double-blind, phase II study compared transdermal application of a gel containing 4-hydroxytamoxifen (4-OHT), an antiestrogenic metabolite of tamoxifen (4 mg/day), to oral tamoxifen (20 mg/day) in preand postmenopausal women with estrogen receptor--positive ductal carcinoma in situ (DCIS).